Table 1 Antibodies used in this study and their respective applications
From: Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis
Antigen | Company | Clone | Conjugation | Application |
|---|---|---|---|---|
CALRm | Statens Serum Institut | 385-06 | In-house: AF647 | Pharmacoscopy MF CALR patients and cell lines |
pSTAT5 | Invitrogen | Polyclonal | In-house: AF647 | Pharmacoscopy MF JAK2 patients |
CD3 | BioLegend | UCHT1 | AF488 | Pharmacoscopy all patients |
CD14 | BioLegend | HCD14 | AF488 | Pharmacoscopy all patients |
CD34 | BioLegend | 581 | PE | Pharmacoscopy all patients |
CALR | Abcam | FMC 75 | PE | Pharmacoscopy cell lines |
HSPA5 (GRP78) | Invitrogen | C38 | AF488 | Immunofluorescence (IF) imaging |
pSTAT5 | Invitrogen | Polyclonal | In-house: AF488 | IF imaging |
CALX | Abcam | EPR3632 | AF488 | IF imaging |
GM-130 | Abcam | EP892Y | AF594 | IF imaging |
IdU | BD Biosciences | B44 | Unconjugated | DNA fibers |
CIdU | Abcam | BU1/75 (ICR1) | Unconjugated | DNA fibers |
IgG1 (mouse) | Invitrogen | Polyclonal | AF488 | DNA fibers |
IgG (rat) | Jackson ImmunoResearch | Polyclonal | Cy3 | DNA fibers |
Ki-67 | Cell Signaling Technology | D3B5 | AF647 | IF imaging and CD34+ drug response analyses |
Cleaved caspase-3 | Cell Signaling Technology | D3E9 | AF647 | CD34+ drug response analyses |
